Expert Case Challenge SGLT2i in CKD: How to overcome clinical inertia?
CME accredited educational session to be held during the ERA-EDTA congress 2021 Fully Virtual
If you are attending ERA-EDTA congress 2021 - Fully Virtual, you are cordially invited to attend this EBAC accredited educational session.
Sunday, June 6, 2021: 09:45 – 10:45 hrs CEST
- To summarize the epidemiology and pathophysiology of patients with kidney disease and diabetes
- To discuss the use of SGLT2 inhibitors, in a risk-based intervention strategy that targets glucose control and cardiovascular risk factors in a patient population with CKD
- To address the remaining questions on the role of SGLT2 inhibition in the management of patients with CKD
- To provide an expert perspective on the role of SGLT2 inhibitors in the treatment of patients with diabetes and CKD
- Introducing a patient with diabetes and CKD Christoph Wanner, MD - Wurzburg, Germany
- Question 1 - Diagnosis and Guidelines - What is the rationale for SGLT2i? Janaka Karalliedde - London, United Kingdom
- Question 2 - Initiating therapy - What are the practical challenges with SGLT2i therapy? Alice Cheng, MD - Toronto, Canada
- Question 3 - Follow up - Defining treatment goals, a shift in paradigm? Peter Rossing, MD - Copenhagen, Denmark
- Expert Case Challenge - Answers and guidance to overcome clinical inertia - All faculty
This programme is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credit(s). Each participant should claim only those hours of credit that have actually been spent in the educational activity. The Accreditation Council for Continuing Medical Education (ACCME®) and EBAC have recognized each other’s accreditation systems as substantially equivalent.
This symposium is funded by an unrestricted educational grant provided by Boehringer Ingelheim/Lilly